Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Acylglycerol kinase is over-expressed in early-stage cervical squamous cell cancer and predicts poor prognosis

Authors: Fei Sun, Ying Xiong, Xiao-Hua Zhou, Qi Li, Lu Xiao, Ping Long, Lin-Jiang Li, Mu-Yan Cai, Yan-Xing Wei, Yan-Lin Ma, Yan-Hong Yu

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Acylglycerol kinase (AGK) had been shown to contribute to cancer progression and unfavorable clinical outcomes of patients. Our study aimed to investigate the expression pattern and clinical significance of AGK in patients with early-stage cervical squamous cell cancer (CSCC). The protein and messenger RNA (mRNA) expression of AGK was analyzed in six cervical cancer cell lines and four paired early-stage CSCC specimens and normal cervical tissues (NCT), using Western blotting and real-time PCR (RT-PCR). And we investigated the AGK protein expression in paraffin-embedded specimens from 140 patients with early-stage CSCC and 30 cases of NCT by immunohistochemistry (IHC). Statistical analyses were performed to evaluate the clinicopathological significance of AGK expression. The expressions of AGK protein and mRNA were significantly up-regulated in cervical cancer cell lines and cancer tissues. IHC analyses revealed that AGK was highly expressed in 93 (66.4 %) of 140 early-stage CSCC specimens, but in none of the NCT. Moreover, AGK expression in early-stage CSCC was significantly correlated with tumor stage (P < 0.001), tumor size (P < 0.001), and tumor type (P < 0.001). Early-stage CSCC patients with high AGK expression level had shorter progress-free survival (PFS) and overall survival (OS) time compared with patients with low AGK expression levels. Univariate and multivariate analyses identified AGK expression level as an independent prognostic factor for survival of early-stage CSCC patients. We showed that AGK was over-expressed in cervical cancer cell lines and clinical tissues, and over-expression of AGK was associated with poor survival outcomes of early-stage CSCC patients. AGK can be used as an independent prognostic marker for early-stage CSCC.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
go back to reference Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, et al. Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101:413–7.PubMed Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, et al. Prognostic factors in stage IB–IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101:413–7.PubMed
3.
go back to reference Lei T, Mao W, Lei T, Dai L, Fang L, Chen W, et al. Incidence and mortality trend of cervical cancer in 11 cancer registries of China. Chin J Cancer Res. 2011;23:10–4.CrossRefPubMedPubMedCentral Lei T, Mao W, Lei T, Dai L, Fang L, Chen W, et al. Incidence and mortality trend of cervical cancer in 11 cancer registries of China. Chin J Cancer Res. 2011;23:10–4.CrossRefPubMedPubMedCentral
4.
go back to reference Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177–83.CrossRefPubMed Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177–83.CrossRefPubMed
5.
go back to reference Curtin JP, Hoskins WJ, Venkatraman ES, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996;61:3–10.CrossRefPubMed Curtin JP, Hoskins WJ, Venkatraman ES, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996;61:3–10.CrossRefPubMed
6.
go back to reference Samlal RA, van der Velden J. Early cervical carcinoma: how to manage high-risk patients after radical hysterectomy. Eur J Obstet Gynecol Reprod Biol. 1999;85:137–9.CrossRefPubMed Samlal RA, van der Velden J. Early cervical carcinoma: how to manage high-risk patients after radical hysterectomy. Eur J Obstet Gynecol Reprod Biol. 1999;85:137–9.CrossRefPubMed
7.
go back to reference En-lin S, Sheng-guo C, Hua-qiao W. The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol. 2010;117(3):417–22.CrossRefPubMed En-lin S, Sheng-guo C, Hua-qiao W. The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol. 2010;117(3):417–22.CrossRefPubMed
8.
go back to reference Garg M, Kanojia D, Saini S, Suri S, Gupta A, Surolia A, et al. Germ cell-specific heat shock protein 70-2 is expressed in cervical carcinoma and is involved in the growth, migration, and invasion of cervical cells. Cancer. 2010;116:3785–96.CrossRefPubMed Garg M, Kanojia D, Saini S, Suri S, Gupta A, Surolia A, et al. Germ cell-specific heat shock protein 70-2 is expressed in cervical carcinoma and is involved in the growth, migration, and invasion of cervical cells. Cancer. 2010;116:3785–96.CrossRefPubMed
9.
go back to reference Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, et al. Involvement of the TGF-ß and ß-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011;17:1317–30.CrossRefPubMed Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, et al. Involvement of the TGF-ß and ß-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011;17:1317–30.CrossRefPubMed
10.
go back to reference Kumar V, Behera R, Lohite K, Karnik S, Kundu GC. P38 Kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 2010;70:10381–91.CrossRefPubMed Kumar V, Behera R, Lohite K, Karnik S, Kundu GC. P38 Kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 2010;70:10381–91.CrossRefPubMed
11.
go back to reference Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, et al. Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci. 2011;102:2255–63.CrossRefPubMed Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, et al. Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci. 2011;102:2255–63.CrossRefPubMed
12.
go back to reference Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol. 2005;169:801–11.CrossRefPubMedPubMedCentral Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol. 2005;169:801–11.CrossRefPubMedPubMedCentral
13.
go back to reference Mouh MA, Wu XX, Okazoe H, Tsunemori H, Haba R, Abou-Zeid AM, et al. Expression of autotoxin and acylglycerol kinase in prostate cancer: association with cancer development and progression. Cancer Sci. 2009;100:1631–8.CrossRef Mouh MA, Wu XX, Okazoe H, Tsunemori H, Haba R, Abou-Zeid AM, et al. Expression of autotoxin and acylglycerol kinase in prostate cancer: association with cancer development and progression. Cancer Sci. 2009;100:1631–8.CrossRef
14.
go back to reference Wang X, Lin C, Zhao X, Liu A, Zhu J, Li X, et al. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Mol Cancer. 2014;13:106.CrossRefPubMedPubMedCentral Wang X, Lin C, Zhao X, Liu A, Zhu J, Li X, et al. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Mol Cancer. 2014;13:106.CrossRefPubMedPubMedCentral
15.
go back to reference Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, et al. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest. 2013;123:2576–89.CrossRefPubMedPubMedCentral Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, et al. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest. 2013;123:2576–89.CrossRefPubMedPubMedCentral
16.
go back to reference Murph MM, Hurst-Kennedy J, Newton V, Brindley DN, Radhakrishna H. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in a549 lung carcinoma cells. Mol Cancer Res. 2007;5:1201–11.CrossRefPubMed Murph MM, Hurst-Kennedy J, Newton V, Brindley DN, Radhakrishna H. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in a549 lung carcinoma cells. Mol Cancer Res. 2007;5:1201–11.CrossRefPubMed
17.
go back to reference Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med. 2010;49:2058–67.CrossRefPubMedPubMedCentral Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med. 2010;49:2058–67.CrossRefPubMedPubMedCentral
18.
go back to reference Wang FQ, Ariztia EV, Boyd LR, Horton FR, Smicun Y, Hetherington JA, et al. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol. 2010;117:88–95.CrossRefPubMed Wang FQ, Ariztia EV, Boyd LR, Horton FR, Smicun Y, Hetherington JA, et al. Lysophosphatidic acid (LPA) effects on endometrial carcinoma in vitro proliferation, invasion, and matrix metalloproteinase activity. Gynecol Oncol. 2010;117:88–95.CrossRefPubMed
19.
go back to reference Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene. 2011;30:1351–9.CrossRefPubMed Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene. 2011;30:1351–9.CrossRefPubMed
20.
go back to reference Cui Y, Lin C, Wu Z, Liu A, Zhang X, Zhu J, et al. AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma. Oncotarget. 2014;5(23):12057–69.CrossRefPubMedPubMedCentral Cui Y, Lin C, Wu Z, Liu A, Zhang X, Zhu J, et al. AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma. Oncotarget. 2014;5(23):12057–69.CrossRefPubMedPubMedCentral
Metadata
Title
Acylglycerol kinase is over-expressed in early-stage cervical squamous cell cancer and predicts poor prognosis
Authors
Fei Sun
Ying Xiong
Xiao-Hua Zhou
Qi Li
Lu Xiao
Ping Long
Lin-Jiang Li
Mu-Yan Cai
Yan-Xing Wei
Yan-Lin Ma
Yan-Hong Yu
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4498-4

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine